A retrospective chart review on oral minoxidil for alopecia in systemic sclerosis, dermatomyositis, mixed connective tissue disease, and undifferentiated connective tissue disease appeared online 8 October 2026 in the Journal of the American Academy of Dermatology, with cardiovascular risk as the headline safety endpoint.

The review carries the formal title "Oral Minoxidil for Alopecia in Systemic Sclerosis, Dermatomyositis, Mixed Connective Tissue Disease, and Undifferentiated Connective Tissue Disease: A Retrospective Chart Review on Cardiovascular Risk." It aggregates real-world prescribing data across four clinically distinct rheumatologic-dermatologic populations.

Why cardiovascular risk anchors the analysis

Low-dose oral minoxidil, repurposed from its original antihypertensive indication, has accumulated a dermatology evidence base for androgenetic alopecia, alopecia areata, and scarring alopecias over the past decade. Doses typically fall between 0.25 mg and 1.25 mg daily, well below the 10–40 mg used in hypertension. Even at these lower doses, the drug retains measurable hemodynamic activity.

Published case series and pharmacovigilance reports document fluid retention, reflex tachycardia, and rare pericardial effusion in otherwise healthy users. The four CTD groups in this review each carry layered cardiac vulnerability:

• Systemic sclerosis predisposes patients to scleroderma renal crisis and pulmonary arterial hypertension.
• Dermatomyositis carries a documented risk of myocarditis and conduction abnormalities.
• Mixed and undifferentiated CTDs blend features of several rheumatologic conditions, often with subclinical cardiac involvement.

In that context, a retrospective chart review functions as a pragmatic audit — capturing prescribed doses, blood-pressure trends, weight changes, and any cardiology referrals already documented in patient charts.

What the author list signals

Lead author Isabella Zappi is listed with twelve coauthors: Archie Spindler, Derek Maas, Devyn Zaminski, Kelley Sharp, Nikita R. Lakdawala, Vikash S. Oza, Seth J. Orlow, Jerry Shapiro, Avrom S. Caplan, Alisa N. Femia, Kristen I. Lo Sicco, and Daniel R. Mazori. Several of these investigators have published earlier work on oral minoxidil and on alopecia in connective tissue disease, positioning the new paper within a continuing research thread rather than as an isolated report.

What dermatologists will want to see in the full text

The published title emphasizes cardiovascular risk, suggesting the authors structured their data extraction around blood-pressure changes, echocardiographic findings where available, dose adjustments, and discontinuation reasons. Clinicians managing this overlap population will look for:

• Total patient count per CTD subgroup
• Mean oral minoxidil dose at initiation and at follow-up
• Documented cardiovascular events and their relationship to dose
• Comparison to expected background rates in CTD patients not on oral minoxidil

Without those details, the chart review's clinical utility remains suggestive rather than prescriptive.

Where this fits in the broader literature

Randomized trials of oral minoxidil in CTD alopecia remain essentially absent — patients on immunosuppression with cardiac involvement typically meet exclusion criteria for industry-sponsored hair-loss trials. Most published evidence outside this niche comes from female pattern hair loss and from chronic telogen effluvium cohorts. JAAD's decision to host a CTD-focused safety review indicates the journal's continued editorial appetite for adverse-event and off-label-use analyses as prescribing expands.

What to watch next

Mazori and colleagues can extend this dataset with prospective blood-pressure monitoring, standardized adverse-event grading, and matched CTD controls not exposed to oral minoxidil. Until that work appears, dermatology clinics treating this overlap population should treat the new chart review as a hypothesis-generating baseline rather than a prescribing guideline.